Find us on:
    You are here:  
  1. Home
  2. Patients
  3. Clinical Trials in Progress

Clinical Trials in Progress

Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia

Purpose of the Study: The study's purpose is to evaluate the effectiveness and safety of LDN in patients with fibromyalgia and analyse its cost-utility both from the government and the healthcare perspective at 12 months follow-up. Brain metabolites and systemic inflammatory biomarkers will be included to evaluate neurobiological mechanisms behind LDN therapeutic effects.
Study Start Date: July 01, 2021
Location: Parc Sanitari Sant Joan de Déu, Barcelona, Spain

Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19

Purpose of the Study: The aim of the study is to assess the safety and clinical efficacy of low-dose naltrexone in reducing the proportion of higher risk patients who progress from mild COVID-19 to a more severe disease category.
Study Start Date: April 01, 2021
Location: Cytocom, Inc.

Impact of Colchicine and Low-dose Naltrexone on COVID-19

Purpose of the Study: The purpose of this study is to explore the impact of low-dose naltrexone (LDN) and colchicine on COVID-19 disease progression in patients hospitalized with moderate COVID-19. Researchers have suggested that a hyperinflammatory response is involved in severe/critical cases of COVID-19. Given LDN acts both to boost the immune system and limit an excessive response, and colchicine has demonstrated clinical utility in inflammatory syndromes, they may prove useful in minimizing the risk of disease progression and associated adverse sequelae.
Study Start Date: January 25, 2021
Location: HealthPartners Institute, Park Nicollet Foundation, Saint Paul, Minnesota

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

Purpose of the Study: The goal of this randomized, placebo-controlled trial is to determine if LDN is effective for treating the pain caused by diabetic neuropathy. LDN's mechanism of action is well suited to treating painful diabetic neuropathy, and LDN shows significant promise as a safe, non-opioid alternative that can decrease pain and improve quality of life for those suffering from this painful condition.
Study Start Date: December 22, 2020
Location: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA

Psychobiological Mechanisms Underlying Chronic Pain

Purpose of the Study: The aim of this study is to investigate the psychobiological mechanisms underlying the negative hedonic shift in chronic pain with a focus on the causal role of neuroinflammation (substudy 1) and the role of dopamine (substudy 2) in functional connectivity of fronto-striatal brain networks and their relation to heightened emotional-motivational pain processing. The drugs that will be used in both substudies will not be utilized as therapeutic clinical interventions, but as modulators of endogenous process and to assess psychobiological mechanisms in pain processing. Substudy 1 incorporates a 12-weeks a pharmacological intervention (low-dose naltrexone or placebo) in patients with fibromyalgia.
Study Start Date: December 19, 2020
Location: Balgrist University Hospital, Zürich, Switzerland

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

Purpose of the Study: This study will assess the use of low dose naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 syndrome (long-COVID-19). Patients will receive LDN and NAD+ treatment for 12 weeks, or will be followed up for 12 weeks (control group). Fatigue and quality of life will be assessed using validated surveys and improvement of scores from baseline levels will be assessed.
Study Start Date: November 10, 2020
Location: AgelessRx, Ann Arbor, Michigan, USA

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Purpose of the Study: Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
Study Start Date: November 02, 2020
Location: AgelessRx, Ann Arbor, Michigan, USA

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, a Randomized Placebo-controlled Prospective Trial

Purpose of the Study: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating condition with symptoms of urinary urgency, frequency, nocturia (waking up at night to void), and pain, without evidence of urinary tract infection or other identifiable causes. LDN has demonstrated improvement of symptoms in conditions associated with IC/PBS. The investigators' hypothesis is that LDN will have greater than 30% reduction in symptoms as defined by the Interstitial Cystitis Symptom Index in patients diagnosed with IC/PBS from baseline when compared to placebo.
Study Start Date: September 01, 2020
Location: NorthShore University HealthSystem, Chicago, Illinois, USA

Low-dose Naltrexone for Bladder Pain Syndrome

Purpose of the Study: Interstitial cystitis/Bladder Pain Syndrome (IC/PBS) is a constellation of symptoms of pelvic discomfort that includes both bladder-related pain as well as urinary frequency, urgency, and nocturia in the absence of an identifiable etiology that affects likely more than 5.4 million patients in the United States. There is a significant overlap in patients with IC/PBS and those with fibromyalgia and chronic pelvic pain syndrome. Low-dose naltrexone (LDN) has been shown to be effective for the treatment of chronic pain conditions. The primary aim of this study is to evaluate if LDN improves pain scores and lower urinary tract symptoms in patients with IC/PBS. A secondary aim is to show that it has a low adverse event profile.
Study Start Date: June 16, 2020
Location: Stanford University, Stanford, California, USA

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

Purpose of the Study: Oral naltrexone was initially FDA approved to treat opioid use disorder and alcohol dependence at doses from 50-100mg/day. At lower doses of 1-5mg/day, naltrexone has been used off-label with success in treatment of several dermatologic conditions including the scarring hair loss disease lichen planopilaris. A recent case series of four patients with lichen planopilaris and a subtype, frontal fibrosing alopecia, treated with oral low-dose naltrexone at 3mg daily showed reduction of itch, clinical evidence of inflammation of the scalp, and of disease progression. There were no reported adverse events. Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 9 months to monitor their progress.
Study Start Date: June 01, 2020
Location: Washington University, Saint Louis, Missouri, USA

Fibromyalgia and Naltrexone: The FINAL Study (FINAL)

Purpose of the Study: This study evaluates the effect of low dose naltrexone (LDN) on pain in women with fibromyalgia (FM). The study is designed as a parallel randomized (1:1) double blind, placebo-controlled superiority trial. Half of the participants will receive treatment with LDN while the other half will receive treatment with placebo. Low dose naltrexone (LDN) is used widely as off label treatment in patients with fibromyalgia, despite the lack of larger randomized controlled trials (RCT) supporting an effect. LDN has antagonistic effect on both opioid receptors and on toll-like receptors in glia cells. Mediated via those receptors, LDN can potentially reduce neuro inflammation and induce homeostasis in the endorphin system in patients with fibromyalgia. The aim of the trial is to investigate whether treatment with LDN has a superior effect compared to placebo on pain among female patients with fibromyalgia, evaluated after 12 weeks of treatment. The study is also exploring secondary aims regarding a possible improvement of other fibromyalgia core symptoms and a possible improvement of global assessment, daily functioning and health-related quality of life. Among the exploratory secondary objectives are changes in muscle exhaustion, physical fitness, pain sensitivity, inhibition of pain, augmentation of pain, and pro-inflammatory cytokines.
Study Start Date: May 01, 2020
Location: Odense University Hospital, University of Southern Denmark, University Hospital Bispebjerg and Frederiksberg, Denemark

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 (SINK COVID-19)

Purpose of the Study: Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo. The trial will measure the ability of low dose naltrexone to reduce the progression of participants with COVID-19. In this study, naltrexone or placebo will be given to participants in early stages of COVID-19 infection in a randomized, double blinded manner, whereas the use of ketamine will be unblinded and given as a rescue agent should a participant progress. Additionally, should a participant be ineligible for the randomized portion of the study due to already being in a more advanced stage of the disease, they will be given the opportunity to enter the trial to receive ketamine without being randomized to naltrexone vs placebo. Participants will continue to receive any standard of care COVID-19 treatment during their participation in this study.
Study Start Date: April 28, 2020
Location: Beaumont Hospital, Royal Oak, Michigan, USA

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin (UH3)

Purpose of the Study: Pain is a common co-morbidity for HIV-positive patients. Prevalence studies suggest that, on average, half of all HIV-positive persons suffer pain. Chronic pain can lead to heavy alcohol use among HIV-positive persons, which may in turn be a barrier to treatment/control of HIV and contribute to spread of HIV. Thus there is an urgent need to address pain among persons with HIV. It is timely and relevant to conduct research on gabapentin, as it has emerged as one of the most commonly prescribed non-opioid medications for pain despite the fact that gabapentin is only FDA approved for "post-herpetic neuralgia" and the literature to support its use for generalized chronic pain is limited. And yet, gabapentin has demonstrated benefits for treatment of alcohol use disorder, and therefore, like naltrexone, it could have a specific role for treating patients with chronic pain and unhealthy alcohol use. This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose naltrexone and gabapentin vs. placebo among HIV-positive persons with heavy alcohol use and chronic pain to provide estimates of their effects on 1) pain (both self-reported and experimental/cold pressor test; 2) inflammation (i.e., levels of inflammatory cytokines IL-6 and TNF-α); and 3) measures of HIV control (CD4 count and viral load).
Study Start Date: April 01, 2020
Location: First St. Petersburg Pavlov State Medical University, St. Petersberg, Russia

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

Purpose of the Study: The purpose of this study is to determine if the addition of Low Dose Naltrexone to standard endometriosis treatments will improve patient reported endometriosis associated pain. The central hypothesis of the research study is that low dose naltrexone (LDN), in combination with hormonal suppression of endometriosis (standard of care), will lead to significant improvement of endometriosis-related pain. The proposal seeks to: 1) determine if the addition of LDN to standard endometriosis treatments will improve patient- reported endometriosis associated pain using daily Visual Analogue Scale (VAS) scores and 2) measure the impact of treatment on quality of life as measured by validated questionnaires including the Endometriosis Health Profile-30 (EHP30) and the Patient's Global Impression of Change (PGIC). The study involves a 12-week intervention period of 4.5 mg daily naltrexone (or placebo) in combination with standard treatment of 5 mg daily norethindrone acetate, and the use of scales to rate daily pain and quality of life.
Study Start Date: July 01, 2019
Location: Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Purpose of the Study: Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis. The purpose of this clinical trial is to determine if low dose naltrexone is effective in improving health-related quality of life (HRQoL) among patients with vasculitis.
Study Start Date: March 29, 2018
Location: University of Pennsylvania, Philadelphia, USA

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache in Children

Purpose of the Study: The purpose of this study is to investigate low-dose naltrexone for the treatment of new daily persistent headache (NDPH) in adolescents ages 10-17. New daily persistent headache (NDPH) is a primary headache disorder with a reported prevalence of 3.5% in adolescents. Patients with NDPH have compromised academic performance, school absence, anxiety, depressed mood, sleep impairment, family disruption, and high health care costs. Little is known about which medications effectively manage and treat NDPH. One proposed medication that may benefit children and adolescents with NDPH is low-dose naltrexone. Naltrexone is an anti-inflammatory agent, similar to the opioid antagonist naloxone. Naltrexone is an effective treatment for opioid addiction, however, it was recently discovered that when taken in low doses (1/10 of the typical dose) naltrexone is capable of reducing the severity of chronic pain symptoms. By acting on glial cells in the nervous system as well as other receptors in the brain, naltrexone is capable of exerting analgesic effects. With this analgesic property, it has been speculated that low-dose naltrexone may be an effective treatment for the management of several chronic pain conditions, including headache.Although more research must be conducted to evaluate long-term effects of using low-dose naltrexone, prior studies show that there are little short-term consequences associated with using this drug as a form of treatment for chronic pain symptoms. Investigators aim to assess the efficacy and safety of low-dose naltrexone in the treatment of patients with NDPH. Adolescents ages 10-17 will be recruited from Boston Children's Hospital Pediatric Headache Program.
Study Start Date: March 02, 2018
Location: Boston Children’s Hospital, Boston, Massachusetts, USA

Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? (LDN-in-FM)

Purpose of the Study: This study evaluates the effect and mechanism of low dose naltrexone for treatment of pain in patients with fibromyalgia. It s a randomised, double-blinded, placebo-controlled, cross-over study.
Study Start Date: June 01, 2016
Location: Multidisciplinary Pain Clinic, Copenhagen & Give, Denmark

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (LDN-CRPS)

Purpose of the Study: The investigators are testing treatment with low-dose Naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN (4.5 mg once daily) or placebo for a period of several weeks. During this period participants will be asked to come to several visits, which will include sensory testing, physical assessments, and questionnaires.
Study Start Date: June 01, 2015
Location: Palo Alto, California, USA

cbd oil: cbd oil for psoriasis bad cbd oil cbd full spectrum vs isolate cbd for weightloss sell cbd oil is smoking cbd oil good for gout how does cbd make you feel reddit in my feelings lyrics brands of cbd oil cbd oil lincoln ne depakote and cbd cbd vape carts ultra cbd reviews canopy kratom why does cbd oil make me tired sativex cbd cbd anti inflammatory cream how to take cbd oil for cancer city properties johannesburg cbd effects of smoking cbd oil cbd wikipedia cannabis plexus hemp or cbd oil passport office cbd belapur we too lo tanning salons melbourne cbd bipolar neurons are rare in adults personal trainer perth cbd koodegras cbd oil sandy ut meaning of effect computer shops brisbane cbd cannabidiol cancer charlottes web cbd near me behavioral inhibition definition cbd healing company half life of cbd oil pharmahemp cbd colitis definition tera crystals cdg type 1p cbd oil for ichthyosis usa med california cbd law therapeutic use definition quicksilver scientific cbd cvs board games youngevity login does cbd oil make your heart race difinition of production sow eden organics cbd oil cbd oil for hidradenitis suppurativa cbd oil cure ezcema cbd for endometriosis zilis 7 hemp cbd oil review cbd oil dollar general

vape: geek vape aegis manual sigelei 200 watt mod vape up usa wismec rx200 kit durban poison vape cartridge lotus vape case cereal killa vape juice snowwolf wocket pod vapor wares vape juices in bulk vapor barrier paper vape shop michigan ecig shops lexington ky vape meridian does 0mg vape juice have nicotine smoke al85 does walgreens sell vape juice voopoo uforce coil trviews e cigarette to help stop smoking vape n juice rockford illinois e cigarette mod supplies for college smok update tool vaping black friday deals e cigarette vaporizer coils does vaping break a fast rda drips vaping heart disease big es vapor effects of vaping on your lungs what does vg stand for in vape juice brynn rumfallo youtube discount prices on premium vape juice bubble gang vape smok mag mod cheap drip coil vape the vapor den vape better than smoking e cig mod starter kit yami vapor taruto review what is steeping vape juice smok tfv8 baby glass trail tech vapor mount uwell valyrian coils stainless steel is there nicotine in coffee uwell caliburn cheap ciro vape uwell watch latch fix vaping hospitalization uwell crown 4 checkmate edition vs standard whats the difference vapor night club how to recharge iron fist uwell smok 225 mag tcr setting on voopoo drag 2 stainless steel wire vape

weight loss: best exercise for weight loss does escitalopram cause weight loss weight loss challenge at work hormone pellets and weight loss ketogenic diet weight loss plan compass weight loss max roth weight loss lose weight fast pills india psychology of weight loss muscle enhancment lucy hale weight loss 2017 not eating for a week weight loss indian diet for weight loss how much does quick weight loss cost cumin seeds for weight loss quick and effective weight loss diet what tea is good for weight loss tomato weight loss pills black coffee diet for weight loss best cla average weight loss on adipex best prescription diet pills 2016 pregnancy hormone for weight loss the best pills for lose weight 600 calories a day weight loss real 2 day diet pills couscous weight loss pills for lose weight green tea for weight loss fast quick weight loss center stuart fl acv benefits for weight loss tighten loose skin after weight loss guy weight loss weight loss medications 2015 lemon peel for weight loss subway weight loss memorial weight loss center protein amount for weight loss vegan recipes weight loss quick weight loss supplements top diet pills 2016 sex after weight loss diet pills that work fast for teenagers weight loss pills green tea how much do diet pills cost lean pills diarrhea pills to lose weight quick weight loss reviews quick belly fat weight loss mariah carey weight loss surgery keto diet plan for weight loss india hormone drops for weight loss xtreme garcinia cambogia good shakes for weight loss

male enhancement: herbs to increase male libido cialis costco inhibited sexual desire does humana cover viagra tadalafil alcohol testosterone booster that really works kamagra gold reviews what is erectile disfunction stretched penis big hard penis what is a good girth foods for erectile dysfunction cure how do you grow your penis vitamins for testosterone teen big penis erectile dysfunction medication how to get large pennis naturally cialis after surgery avg male penis size top dicks small penis ring sildenafil tablets 100mg max performer pills edge nutrition test booster guys getting hard best dick enlargement pills baolong pills how to ejaculate more vasoplexx pills black panther rhinos length and girth surgery hercules sex boys penas how to make your peni bigger fast define enlarge enlarge your penis can i order antibiotics online smoothies for male enhancement magnesium for erectile dysfunction how to make a dick grow the natural vitamins monster test testosterone review types of sexual dysfunctions why take testosterone boosters can impotence be reversed define treat for hims review reddit erectile dysfunction in men types of penis growth hormone boosters white bumps on tip of penis all natural erection pills omega xl at walmart yoga for sexuality for men